Live From WCLC 2026: Tuesday Highlights & Meeting Summary

Episode
382
Soundcloud
Share

In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap key findings from day three of the conference, featuring major advances that move targeted therapies earlier in the treatment of lung cancer. Guests Dr. Roy Herbst, Dr. Julia Rotow, and Dr. Daniel Tan discuss new data from DESTINY-Lung04, ADAURA, and REZILIENT3 and what these findings could mean for clinical practice.

Guest
Stephen Liu
Stephen Liu

MD

Chief of Hematology and Oncology
Georgetown University
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Julia Rotow
Julia Rotow

MD

Clinical Director and Research Director
Lowe Center for Thoracic Oncology
Dana-Faber Cancer Institute
Roy Herbst
Roy Herbst

MD

Director, Dartmouth Cancer Center
Professor, Geisel School of Medicine at Dartmouth
Daniel Tan
Daniel Tan

MD

Senior Consultant, Medical Oncology
National Cancer Centre Singapore
Professor, Duke-NUS Medical School
Senior Clinician-Scientist, Genome Institute of Singapore

Other Podcast